Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ted M Ross

Showing results (201-210 of 345) with videos related to

Pageof 35
Sort By:
Annals of the American Thoracic Society|August 23, 2014
Challenges and future in vaccines, drug development, and immunomodulatory therapyHeather M Kling, Gerard J Nau, Ted M Ross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2019
A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against HemagglutininGiuseppe A Sautto, Greg A Kirchenbaum, Rodrigo B Abreu, et al.
Vaccines|October 2, 2019
Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in FerretsMagen E Francis, Mara McNeil, Nicholas J Dawe, et al.
Vaccine|September 5, 2019
Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccineYael Bar-Peled, Jiachen Huang, Ivette A Nuñez, et al.
Vaccines|January 8, 2025
Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune<sup>®</sup> Generate Broadly Protective Antibody Responses in Mice and FerretsJames D Allen, Xiaojian Zhang, Jessica M Medina, et al.
The Journal of Infectious Diseases|March 27, 2012
A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infectionBrendan M Giles, Corey J Crevar, Donald M Carter, et al.
The Journal of Infectious Diseases|June 27, 2025
Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge TrialYao Lu, James D Allen, Ted M Ross, et al.
Human Vaccines & Immunotherapeutics|February 15, 2014
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine designAnne S De Groot, Lenny Moise, Rui Liu, et al.
Journal of Virology|September 7, 2012
Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodiesSwati Verma, Milena Dimitrova, Ashok Munjal, et al.
The Journal of Infectious Diseases|August 25, 2023
Assessment of Humoral Immune Responses to Repeated Influenza Vaccination in a Multiyear Cohort: A 5-Year Follow-upMeng-Hsuan Sung, W Zane Billings, Michael A Carlock, et al.
Pageof 35

Showing results (201-210 of 345) with videos related to

Sort By:
Pageof 35
Annals of the American Thoracic Society|August 23, 2014
Challenges and future in vaccines, drug development, and immunomodulatory therapyHeather M Kling, Gerard J Nau, Ted M Ross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2019
A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against HemagglutininGiuseppe A Sautto, Greg A Kirchenbaum, Rodrigo B Abreu, et al.
Vaccines|October 2, 2019
Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in FerretsMagen E Francis, Mara McNeil, Nicholas J Dawe, et al.
Vaccine|September 5, 2019
Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccineYael Bar-Peled, Jiachen Huang, Ivette A Nuñez, et al.
Vaccines|January 8, 2025
Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune<sup>®</sup> Generate Broadly Protective Antibody Responses in Mice and FerretsJames D Allen, Xiaojian Zhang, Jessica M Medina, et al.
The Journal of Infectious Diseases|March 27, 2012
A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infectionBrendan M Giles, Corey J Crevar, Donald M Carter, et al.
The Journal of Infectious Diseases|June 27, 2025
Evaluating the Breadth and Reliability of Influenza Vaccine Protection Indicators: a Secondary Analysis of an Animal Challenge TrialYao Lu, James D Allen, Ted M Ross, et al.
Human Vaccines & Immunotherapeutics|February 15, 2014
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine designAnne S De Groot, Lenny Moise, Rui Liu, et al.
Journal of Virology|September 7, 2012
Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodiesSwati Verma, Milena Dimitrova, Ashok Munjal, et al.
The Journal of Infectious Diseases|August 25, 2023
Assessment of Humoral Immune Responses to Repeated Influenza Vaccination in a Multiyear Cohort: A 5-Year Follow-upMeng-Hsuan Sung, W Zane Billings, Michael A Carlock, et al.
Pageof 35